On March 2, 2025, Akari Therapeutics entered into a securities purchase agreement to sell 6,637,626 unregistered American Depository Shares and warrants, expecting to raise approximately $7.1 million for working capital. The offering is set to close on March 5, 2025, and includes various tiers for investors based on their commitment amounts.